Key Immune Cells Identified That Could Strengthen Flu Vaccines

Influenza remains a significant cause of illness in the United States, responsible for over 35,000 annual deaths. Although flu vaccines are generally effective in preventing severe illness when administered via injection, they often fail to prevent infection in the nose and lungs. Nasal vaccines, which target immunity at the site of initial virus entry, have shown inconsistent efficacy.

A new study, published in Nature Immunology, identifies a previously underexplored group of immune cells that could enhance the effectiveness of these nasal vaccines.

The study, titled "Monocyte-derived galectin-1 hi cells provide innate immune help in the generation of functional memory CD8+ T cells," reveals that a long-lived population of monocytes, which were once considered short-lived immune cells, can persist in the lungs for months after an influenza infection. These monocytes do not disappear but instead support the formation of immune memory by aiding the survival and functionality of memory T cells in the lung.

This discovery challenges the conventional belief that immune memory is solely driven by T and B cells, demonstrating that innate immune cells also play a crucial and enduring role.

Minsoo Kim, a professor of microbiology and immunology at the University of Rochester Medicine, explains that tissue-resident memory T cells act as the first line of defense at the site of infection, reacting rapidly and limiting viral spread. However, most existing flu vaccines, particularly those administered via injection, do not effectively build strong immune memory in the airways, thus failing to provide comprehensive protection against initial infection and transmission.

The researchers discovered that a specific subset of monocytes, after being recruited and differentiated, transform into memory-stage cells and persist in the lung for over four months post-infection. These cells produce the protein galectin-1, which is essential for activating and sustaining tissue-resident memory T cells. When galectin-1 was introduced into a nasal flu vaccine in mice, the immune response in the lungs was significantly bolstered.

The study indicates that memory-stage CCR2-tdTomato+ cells in the lung align with CD8+ TRM cells and secrete galectin-1, which directly activates CD8+ T cells and enhances their function through transforming growth factor-β sensing.

This breakthrough not only opens the door to innovative vaccine strategies but also suggests that targeting innate immune cells could improve respiratory vaccines. Galectin-1 has been identified as a powerful immune signal that could serve as an adjuvant to enhance mucosal immunity, a new approach that could markedly improve respiratory vaccine efficacy. Beyond influenza, these findings may have implications for other respiratory viruses, including those causing seasonal illnesses and pandemics.

Kim and her team are now working to develop more stable forms of galectin-1 that could be safely used as a vaccine additive. Successful translation of these findings to humans could revolutionize respiratory vaccine design, moving away from focusing solely on antibody responses or circulating immune cells and instead targeting the long-term behavior of immune cells residing in the lungs.

By leveraging this "helper" population of immune cells, researchers hope to develop vaccines that not only prevent severe disease but also mitigate infection earlier and more effectively at the point of entry.